León-Díaz M, Santiago-Escobar Y, Baltazar-Gutierrez O

Language: Spanish
References: 21
Page: 172-177
PDF size: 220.54 Kb.

ABSTRACT

Objective: To describe the clinical and sociodemographic characteristics of patients with Mpox virus treated at a family medicine service. Methods: A descriptive cross-sectional study was conducted. A search was performed in the electronic medical record database for patients with a PCR-confirmed diagnosis of Mpox virus infection who were treated at the Family Medical Unit No. 28 “Gabriel Mancera” of the Mexican Social Security Institute (IMSS) in Mexico City during 2022. Clinical and sociodemographic data, as well as comorbidities, were extracted. Descriptive statistics were performed. Results: A total of 51 patients were included, 98% (n= 50) were male, 95% (n= 49) were men who have sex with men (MSM), mean age 36 years (± 9.3); 80% (n= 41) reported not using a condom during sexual relations, 70% (n= 36) were people living with human immunodeficiency virus (HIV), and 82% (n= 42) reported a previous history of a sexually transmitted infection. The most frequent route of transmission was sexual, in 74% (n= 38). The distribution of vesiculopustular lesions was as follows: 72% (n= 37) on upper limbs, 70% (n=36) on the trunk, and 66% (n= 34) in the anogenital region. Proctitis was present in 13.7% (n=7). The estimated recovery time was 25 days. Conclusions: Mpox virus infection primarily affected young msm men, with hiv comorbidity. Sexual transmission was predominant, and lesions were located were mostly located on the upper limbs, trunk, and anogenital area. The course of the disease was self-limited, with recovery in approximately 25 days.

REFERENCES

1. Louten J. Chapter 16 – Poxviruses. In: Essential Human Virology. 2nd ed. Academic Press; 2023. p: 323–340

2. Reina J, Reina N. ¿Deberíamos empezar a preocuparnos por la viruela de los monos? Med Clin (Barc). 2018;151(8):320-322.

3. Tiecco G, Degli A, Storti S, Tomasoni L, Castelli F, Quiros E. Monkeypox, a literature review: What is new and where does this concerning virus come from? Viruses. 2022;14(9):1894.

4. Pan D, Nazareth J, Sze S, Martin C, Decker J, Fletcher E, et al. Transmission of MPOX: A narrative review of environmental, viral, host and population factors in relation to the 2022 international outbreak. J Med Virol. 2023;95(2):e28534.

5. Mazharul I, Pronesh D, Rijwana R, Syed S, Ariful I, Elmoubashar F, et al. Pathogenicity and virulence of monkeypox at the human-animal-ecology interface. Virulence. 2023;14(1):2186357.

6. Junjie L, Hui X, Chunhua W, Mengjun T, Changcheng W, Fan X, et al. Mpox (formerly monkeypox): pathogenesis, prevention and treatment. Signal Transduction and Targeted Therapy. 2023;8(1):458.

7. Petersen E, Kantele A, Koopmans M, Asogun D, Yinka A, Chikwe I, et al. Human monkeypox: Epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am. 2019;33(4):1027-1043.

8. Patel M, Adnan M, Aldarhami A, Bazaid A, Saeedi N, Alkayyal A, et al. Current insights into diagnosis, prevention strategies, treatment, therapeutic targets, and challenges of monkeypox (Mpox) infections in human populations. Life. 2023;13(249):1-17.

9. Rodríguez F, Nájera L, Suárez D, Silvestre G, García D, Roustan G, et al. Clinical, histopathologic, immunohistochemical, and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain. J Am Acad Dermatol. 2023;88(2):336-343.

10. Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022;22(9):1321-1328.

11. Patel A, Bilinska J, Tam J, Da Silva F, Mason C, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022; 378:e072410.

12. Lao T, Blitz A, Gandhi M, Adamson P, Park I, Bolan G, et al. A position statement on Mpox as a sexually transmitted disease. Clin Infect Dis. 2023;76(17):1508-1512.

13. Centers for Disease Control and Prevention CDC. Clinical Considerations for Mpox in Children and Adolescents in the U.S. 2024 [Internet]. [Citado 2024 Oct 2] Disponible en: https://www.cdc.gov/mpox/hcp/clinical-care/pediatric.html?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/clinicians/pediatric.html

14. Bryer J, Freeman E, Rosenbach M. Monkeypox emerges on a global scale: A historical review and dermatologic primer. J Am Acad Dermatol. 2022;87(5):1069-1074.

15. Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini L, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy. Euro Surveill. 2022;27(22):2200421.

16. Cano A, Pérez S, Velasco C, Mata A, Pérez E, González S. Viruela símica: a propósito de otra pandemia. J SIDVI. 2022;1(1):9-13

17. Lum F, Torres A, Tay M, Lin R, Lye D, Rénia L. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol. 2022;22(10):597-613.

18. Zamudio I, Pastrana A, Ridaura C, Amaral D, Rodríguez O, Serrano R, et al. Epidemiología de Mpox (antes viruela símica) en un Hospital de la Ciudad de México. Enf Inf Microbiol. 2023;43(3):151-159

19. Global Mpox trends [internet] [Citado 2025 Abr 17]. Disponible en: https://worldhealthorg.shinyapps.io/mpx_global/#sec-global

20. Núñez I, García-Grimshaw M, Ceballos-Liceaga SE, Toledo-Salinas C, Carbajal-Sandoval G, Sosa-Laso L, et al. Epidemiological and clinical characteristics of patients with human monkeypox infection in Mexico: a nationwide observational study. Lancet Reg Health Am. 2023; 17:100392.

21. Titanji BK, Hazra A, Zucker J. Mpox clinical presentation, diagnostic approaches, and treatment strategies: A review. JAMA. 2024;332(19):1652-1662.